Ecole Polytechnique Fédérale de Lausanne (EPFL), Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland.
Curr Top Dev Biol. 2010;92:411-55. doi: 10.1016/S0070-2153(10)92013-9.
In recent years a substantial body of evidence derived from not only preclinical but also clinical studies has accumulated in support of Notch signaling playing important oncogenic roles in several types of cancer. The finding that activating Notch mutations are frequently found in patients suffering from acute lymphoblastic leukemia is one of the best examples for a critical role of Notch signaling in cancer, a fact that motivated many researchers and clinicians to study the role of Notch also in solid tumors. Hence Notch signaling has gained increasing attention as a potential therapeutic target. In this book chapter we would like to discuss our current knowledge of Notch signaling within different types of solid cancers as well as advantages and disadvantages of potential new therapies that try to target the oncogenic properties of Notch signaling.
近年来，不仅来自临床前研究，也来自临床研究的大量证据积累起来，支持 Notch 信号在几种类型的癌症中发挥重要致癌作用。发现激活 Notch 突变经常在患有急性淋巴细胞白血病的患者中发现，这是 Notch 信号在癌症中具有关键作用的最好例子之一，这一事实促使许多研究人员和临床医生研究 Notch 在实体肿瘤中的作用。因此， Notch 信号作为一种潜在的治疗靶点越来越受到关注。在这一章中，我们将讨论我们目前对不同类型实体癌中 Notch 信号的认识，以及试图针对 Notch 信号致癌特性的潜在新疗法的优缺点。
